The dawn of a revolution in personalized lung cancer prevention.
Cancer Prev Res (Phila)., Jul;4(7):949-53 (2011)
Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.
Cancer Res., Oct;71(19):6270-81 (2011)
Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
Oncology., 81(1):12-20 (2011)
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
Mol. Cancer Ther., Dec;10(12):2415-25 (2011)
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.
Mol. Cell. Biol., Dec;31(24):4938-50 (2011)
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
J. Biol. Chem., Jan;287(1):257-67 (2012)
Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data.
Biomed Eng Online., 10:97 (2011)
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.
Mol. Cell., Dec;44(6):864-77 (2011)
The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.
Cancer Prev Res (Phila)., Apr;5(4):612-20 (2012)
Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts.
Integr Biol (Camb)., Jun;4(6):633-40 (2012)
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.
J Thorac Oncol., May;7(5):866-72 (2012)
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Cancer Prev Res (Phila)., Jun;2(6):538-45 (2009)
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Mol. Cancer Ther., Sep;8(9):2575-85 (2009)
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
J. Biol. Chem., May;285(21):16096-104 (2010)
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Neoplasia., Apr;12(4):346-56 (2010)
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Cancer., Aug;116(16):3903-9 (2010)
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Cancer Biol. Ther., Dec;7(12):1952-8 (2008)
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53.
J. Biol. Chem., Nov;285(45):34557-65 (2010)
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Neoplasia., Oct;12(10):848-55 (2010)
ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.
J. Biol. Chem., Dec;285(53):41310-9 (2010)